EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug
Feb 28 (Reuters) - The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Alzheimer's drug, Leqembi, after concluding a safety review.
The European Medicines Agency (EMA) in late January said the European Commission had requested a review of additional safety information for the drug, following its November approval to treat some patients with early Alzheimer's disease.
The Commission, which is EU's executive arm, must accept EMA recommendations for new drugs before they are made available to patients. It did not say why it had requested a safety review for Leqembi.
Biogen's head of development, Priya Singhal, said the "reaffirmation" underscores Leqembi's safety profile, adding that the company was working with Eisai to make the treatment available to patients in Europe as soon as possible.
The EMA's human medicines committee last year backed Leqembi for a narrower set of patients than those evaluated in a late-stage trial, reversing its initial refusal to approve the drug due to the risk of serious brain swelling.
Leqembi can cause brain swelling or bleeding, and patients must also undergo an MRI before treatment and several during treatment to monitor this risk, according to the U.S. Food and Drug Administration.
The therapy, also known as lecanemab, is already approved in the U.S., China, Hong Kong, Israel, Japan and South Korea, and could become Europe's first drug approved to treat the neurodegenerative condition directly rather than treat its symptoms.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
June 9 (Reuters) - UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's ( opens new tab shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above as a precautionary measure. The vaccine, IXCHIQ, was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in February to protect people aged 18 years and above against chikungunya, but is not yet available in the UK market. "The decision to restrict the licence until further review is based on global data which has highlighted 23 cases of serious adverse reactions, including two cases reporting a fatal outcome, in people aged from 62 to 89 years of age who received the vaccine," the regulator said. The adverse events, opens new tab were reported in the French overseas territory of La Reunion, where a chikungunya outbreak was reported earlier this year. MHRA's decision comes after the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) in May suspended, opens new tab the use of the vaccine in the age group. The French Government was the first to take the step in April.
STV News
an hour ago
- STV News
Alzheimer's research suffers 'devastating blow' after new drug rejected by NHS
A woman who has Alzheimer's disease has said the progression of research has suffered a 'devastating blow' after a new drug was rejected for use by NHS Scotland. Donanemab delays the onset of dementia and works by targeting a cause of the disease, rather than just treating its symptoms. But the Scottish Medicines Consortium says there isn't enough evidence to prove how well it works. Recently retired Rynagh has lived an enviable life, growing up in Ireland, moving to the US, and attending New York University. Coming to Scotland, she expected to live out the rest of her life in peaceful retirement. Instead, she found out she had dementia. She's now thrown into finding a cure for Alzheimer's – and says the rejection of this drug is a massive blow. 'What would it take to approve a drug for dementia?', she said. 'Because it seems to be a lost in space for people. There aren't annual check-ups or anything like there are with other diseases. So there's no record of decline, which is unusual when you think about how progress is made with other diseases over time. 'Think about polio, leprosy, and cancer. They were known many years ago, but we don't talk about them because of the needs and the cost. 'And I understand that cost is a factor, but the burden on society, even in comparison to those other diseases, is tremendous. Absolutely. And only tremendous. It's not just the individual, it's the community, it's the family. 'It's the cost to the next generation for what they lose out by having to provide that care and not being able to support their own families, immediate families, in the way that they will.' Donanemab works when antibodies are given by infusion into a vein in the arm – they then bind with amyloids in the brain, a protein that builds up in Alzheimer's patients, and leads to cognitive decline. Those antibodies trigger immune cells, which clear the amyloid – and slow down the alzheimer's process. The Scottish Medicines Consortium rejected donanemab for use on the NHS as it said there wasn't 'enough evidence of how well it works.' Meanwhile manufacturer Lilly claims the decision 'does not consider … the clinical efficacy and cost-effectiveness' of the drug. It's left campaigners worried about the future of dementia research. Henry Simmons, chief executive of Alzheimer Scotland, said: 'The process that all drugs go through at present at the both the NHS in Scotland and England is a reasonable process however, we don't think it is a reasonable way to tackle the issues we face in terms of the size and scale of dementia, and what we are calling for is a rethink on that.' There's hope the SMC will reconsider the drug, but in the meantime, Rynagh hopes people living with dementia don't give up – and that awareness of the illness continues to grow. 'Well, when it comes down to it, it is the public', she added. 'And if the public doesn't have the awareness, they won't push. 'You know, like 66% is that about two thirds of people with dementia are women. Women typically are the caregivers, but then they need the care and it becomes this cycle and it is increasing instead of decreasing. 'And also with the population pyramid is kind of changing as well. We know that that the elderly population is getting bigger and that's it's a disaster that you should be able to see. 'It's not that you're seeing one seventh of the iceberg. We're now coming to the point where it's so far above the water, it should be that you can go around us and go through it and disperse it, but are not even talking about it at the level that we need to be talking about it.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Daily Mirror
4 hours ago
- Daily Mirror
Girl, 12, dies after doctors mistook fatal tumour for 'tummy bug'
Jackie Dunlop has urged parents to "trust their gut" after losing her daughter Ava Nelson from a condition which GPs initially dismissed as something minor A mum is urging parents to trust their instincts after her daughter's tummy bug turned out to be an inoperable brain tumour. Jackie Dunlop from North Ayrshire became concerned when her daughter Ava Nelson, then aged 10, suffered with severe headaches and sickness for three weeks. Following visits to the GP and her local hospital, the young girl was a viral infection or a gastric bug. However, after the fourth week of Ava feeling unwell, Jackie pushed for more testing and what followed shocked the 38-year-old to the core. An MRI revealed a pressure of Ava's brain, caused by a large mass, and she was rushed up to the Royal Hospital for Children in Glasgow. She had to have an emergency operation to relieve the pressure and a biopsy a week later revealed Ava had a high-grade glioblastoma. The family were told she had just six to 12 months to live, but Ava outlived that prediction and passed away nearly two years later in April 2024, aged 12. Now Jackie, from Kilwinning, who previously worked as a carer, is telling parents not to ignore their own suspicions regarding their child's health. She said: "We thought it was a sickness bug. But going into week three I started to worry. Everyone put it down to a viral sickness bug. Four weeks I had been fighting with doctors. The surgeon told us if we didn't fight she'd have been dead within a week because the pressure was that bad." She continued: "I always say to any mother go with your gut instinct if you feel that something is wrong with your child. If you feel something is wrong then go get them checked. If you aren't getting anywhere stand your ground and make sure you get the help and support you need until you have the right answers. Mothers know their child best." Ava began experiencing headaches, dizziness, and balance issues in May 2022. Despite numerous GP appointments and hospital visits, her symptoms were dismissed as just a viral illness, reports Glasgow Live. Growing concerned about her daughter's health, Jackie refused to accept this and persevered for further medical attention at Crosshouse Hospital's children's ward. Jackie recounted: "To look at her you wouldn't know anything was wrong. They agreed to do blood tests – Ava then started vomiting. She started declining but the blood tests came back fine. I pushed for a scan." The persistence paid off when an MRI scan showed a brain tumour. Ava was rushed to the Royal Hospital for Children in Glasgow on May 31, 2022. Jackie said: "They told us Ava has severe pressure on her brain. They found a tumour. The pressure was caused by the tumour." Ava underwent emergency surgery the following day; however, doctors couldn't fully remove the tumour due to its location. The biopsy results returned on June 8, 2022, confirming Ava's diagnosis with cancer. Jackie revealed: "The hardest part for me was that wasn't going to survive. They gave us six to 12 months." Ava bravely endured 12 weeks of simultaneous radiotherapy and chemotherapy, which resulted in her needing a feeding tube after the treatment caused a rupture in her stomach. Her parents, Jackie and Roland, made the heart-wrenching decision not to disclose Ava's terminal prognosis, choosing instead to create cherished memories. Jackie shared: "We were trying to normalise life." The family dedicated themselves to ensuring their beloved "wee warrior" had as many joyous moments as possible, despite their own sorrow. Jackie said: "As a family we did everything in our willpower to make sure that the time we had left with our wee warrior was full of fun filled memories as much as it was killing us inside." In spring 2023, Ava was admitted to Robin House Children's Hospice, where she fought for another year before passing away on April 16, 2024, with her loving parents and sisters, aged nine and 17, by her side. Jackie recalled: "They moved her into the rainbow room. It was the most peaceful room." Jackie now aims to inspire other parents to trust their instincts about their children's health. She added: "Ava was quiet as a mouse. She was quite shy and timid. But she was sweet and loving. She was the best."
